A. Caumont

发表

miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial.

P. Laurent-Puig, C. Lepage, S. Martin-Lannerée, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Functional Interactions of Human Immunodeficiency Virus Type 1 Integrase with Human and Yeast HSP60

C. Calmels, V. Parissi, A. Caumont, 2001, Journal of Virology.

Selection of amino acid substitutions restoring activity of HIV-1 integrase mutated in its catalytic site using the yeast Saccharomyces cerevisiae.

C. Calmels, V. Parissi, A. Caumont, 2000, Journal of molecular biology.

Biochemical and random mutagenesis analysis of the region carrying the catalytic E152 amino acid of HIV-1 integrase.

C. Calmels, V. Parissi, A. Caumont, 2004, Nucleic acids research.

Inhibition of HIV-1 integrase-catalysed reaction by new DNA minor groove ligands: the oligo-1,3-thiazolecarboxamide derivatives.

V. Parissi, A. Sinyakov, A. Caumont, 2000, European journal of medicinal chemistry.

The lethal phenotype observed after HIV-1 integrase expression in yeast cells is related to DNA repair and recombination events.

C. Calmels, V. Parissi, M. Bonneu, 2003, Gene.

Primary HIV-1 drug resistance in Abidjan (Côte d'Ivoire): a genotypic and phenotypic study.

R. Salamon, B. Masquelier, F. Dabis, 2002, AIDS.

High affinity interaction of HIV‐1 integrase with specific and non‐specific single‐stranded short oligonucleotides

V. Parissi, G. Nevinsky, A. Caumont, 1999, FEBS Letters.

Whole blood real-time quantitative PCR for cytomegalovirus infection follow-up in transplant recipients.

H. Fleury, C. Dromer, A. Caumont, 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

HIV-1 integrase interacts with yeast microtubule-associated proteins.

E. Bon, P. Durrens, C. Calmels, 2002, Biochimica et biophysica acta.

Inactivation of the SNF5 transcription factor gene abolishes the lethal phenotype induced by the expression of HIV-1 integrase in yeast.

V. Parissi, A. Caumont, S. Litvak, 2000, Gene.

HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs.

B. Masquelier, H. Fleury, P. Roques, 2003, AIDS research and human retroviruses.

Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy.

J. Ragnaud, M. Dupon, H. Fleury, 2003, The Journal of infectious diseases.

Sequence analysis of env C2/V3, gag p17/p24, and pol protease regions of 25 HIV type 1 isolates from Ho Chi Minh City, Vietnam.

H. Fleury, F. Barré-Sinoussi, P. Roques, 2001, AIDS research and human retroviruses.

Comparison of capillary electrophoresis sequencing with the new CEQ 2000 DNA Analysis System to conventional gel based systems for HIV drug resistance analysis.

H. Fleury, A. Caumont, I. Pellegrin, 2001, Journal of virological methods.

A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.

B. Roques, N. Morellet, C. Lenoir, 2002, Journal of molecular biology.

Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study)

D. Breilh, P. Morlat, H. Fleury, 2002, AIDS.

Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen.

H. Fleury, J. Pellegrin, A. Caumont, 2001, AIDS.